Citations

Clear

6273 citation(s) found for "To, Andrew".

Open-Source Whole Slide Image Preparation and Viewing Pipeline
Norgan, Andrew P. , Shah, Kabeer , Maleszewski, Joseph J. , Norgan, Andrew Paul, Shah, Kabeer Kevin, Juskewitch, Justin Eddie, Maleszewski, Joseph John, Norgan, Andrew P , Juskewitch, Justin E.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 30, 2018 | Volume: 142 | Issue: 12 | Pages: 1454-1455

10.5858/arpa.2018-0323-le | PMID 30500278 Get It

A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants
Jensen, Allan , Wiensch, Ashley , Lee, Alice W. , Ness, Roberta B., Salvatore, Maxwell , Tworoger, Shelley S. , Whittemore, Alice S. , Sieh, Weiva , Goode, Ellen L. , Goodman, Marc T. , Chenevix‐Trench, Georgia , Rossing, Mary Anne, Webb, Penelope M. , Terry, Kathryn L. , Fortner, Renée T. , Menon, Usha , Gayther, Simon A. , Wu, Anna H. , Song, Honglin , Brooks‐Wilson, Angela , Thompson, Pamela J., Chang‐Claude, Jenny , Schildkraut, Joellen M. , Le, Nhu D. , Wentzensen, Nico, Trabert, Britton , Høgdall, Estrid , Huntsman, David G. , Pike, Malcolm C. , Pearce, Celeste Leigh , Salvatore, Maxwell , Anton-Culver, Hoda , Goode, Ellen L , Fortner, Renée T , Wu, Anna H. , Cramer, Daniel W , Modugno, Francesmary , Trabert, B , Pike, Malcolm C , Pearce, Celeste Leigh , Tworoger, Shelley S , Webb, Penelope M , Jensen, Allan , Menon, Usha , Brooks-Wilson, Angela R , Sieh, Weiva , Chenevix-Trench, Georgia , Høgdall, Estrid , Goodman, Marc T , Kim, Sehee , Wang, Miao , Tyrer, Jonathan P. , Liu, Gang , Anton‐Culver, Hoda , Olson, Sara H. , Berchuck, Andrew , Doherty, Jennifer A. , Giles, Graham G. , Ziogas, Argyrios , Bandera, Elisa V. , Cook, Linda S. , Cramer, Daniel W. , Milne, Roger L. , Winham, Stacey J. , Kjær, Susanne K. , Modugno, Francesmary , Harris, Holly R. , Pharoah, Paul D.P. , Mukherjee, Bhramar

Mayo Clinic

International Journal of Cancer | November 30, 2018 | Volume: 144 | Issue: 9 | Pages: 2192-2205

10.1002/ijc.32029 | PMID 30499236 Get It

As a follow‐up to genome‐wide association analysis of common variants associated with ovarian carcinoma (cancer), our study considers seven well‐known ovarian cancer risk factors and their interactions with 28 genome‐wide significant common genetic variants. The interaction analyses were based on data from 9971 ovarian cancer cases and 15,566 controls from 17 case–control studies. Likelihood ratio and Wald tests for multiplicative interaction and for relative excess risk due to additive interaction were used. The top multiplicative interaction was noted between oral contraceptive pill (OCP) use (ever vs. never) and rs13255292 (p value = 3.48 × 10−4). Among women with the TT genotype for this variant, the odds ratio for OCP use was 0.53 (95% CI = 0.46–0.60) compared to 0.71 (95%CI = 0.66–0.77) for women with the CC genotype. When stratified by duration of OCP use, women with 1–5 years of OCP use exhibited differential protective benefit across genotypes. However, no interaction on either the multiplicative or additive scale was found to be statistically significant after multiple testing correction. The results suggest that OCP use may offer increased benefit for women who are carriers of the T allele in rs13255292. On the other hand, for women carrying the C allele in this variant, longer (5+ years) use of OCP may reduce the impact of carrying the risk allele of this SNP. Replication of this finding is needed. The study presents a comprehensive analytic framework for conducting gene–environment analysis in ovarian cancer.
Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).
Zvinovski, Filadelfiya , Hudson, Catherine O., Hundley, Andrew F., Evans, Cynthia, Suresh, Anupama , Stephens, Julie , Carpenter, Kristen M. , Ramaswamy, Bhuvaneswari , Reinbolt, Raquel E. , Williams, Nicole , Sardesai, Sagar , Loprinzi, Charles L. , Sardesai, Sagar , Quick, Allison , Noonan, Anne M. , VanDeusen, Jeffrey , Wesolowski, Robert , Stover, Daniel G. , Smith, Karen L. , Faubion, Stephanie S. , Lustberg, Maryam B.

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 202-202

10.1200/jco.2018.36.34_suppl.202 Get It

202 Background: Fractional CO2 laser therapy is an emerging treatment for GSM. The objective of this study was to determine the feasibility, tolerability and preliminary efficacy of fractional CO2 laser therapy in BC survivors. Methods: This was a single arm feasibility study of BC survivors with dyspareunia and/or vaginal dryness. Participants received three treatments with office-based fractional CO2 laser on at least 30 day intervals and returned for a one-month follow-up. Feasibility was defined as treatment completion without serious adverse events (SAE) in a minimum of 80% of patients. Primary efficacy was evaluated using the mean change (∆) in the score on the Vaginal Assessment Scale (VAS). Secondary efficacy endpoints included mean ∆ in scores on the Female Sexual Function Index (FSFI) and Urogenital Distress Inventory (UDI). Descriptive statistics (means and 95% confidence intervals (CI) for continuous variables and proportions for categorical variables) were used. Results: The study is ongoing with 65 patients enrolled. To date, 37 patients have completed all study treatments and follow-up. Median age for those who have completed treatment was 57 years (range 34-72). Most were ER/PR positive (78%) and Her 2 negative (81%) with stage I (43%) or II (41%) BC. Ninety-five percent were receiving endocrine therapy, most commonly aromatase inhibitors (73%). No SAEs were reported in the 37 patients who have completed study treatments and their outcomes are as follows. Based on the VAS, 78% reported moderate-severe dyspareunia and 89% reported moderate-severe vaginal dryness at baseline. At follow up, 28% reported moderate-severe dyspareunia and 28% reported moderate-severe vaginal dryness. The VAS score improved from baseline to follow up (mean ∆ 4.1; 95% CI [3.1, 5.1]). Similarly, the FSFI score improved (mean ∆ -10.0; 95% CI [-13.2, -6.9]) and the UDI score improved (mean ∆ -5.7; 95% CI [-10.1, -1.3]). Final efficacy analysis will be reported once all patients have completed all time points. Conclusions: Fractional CO2 laser treatment is feasible and tolerable in BC survivors and may reduce symptom burden from GSM. A randomized controlled trial with sham laser is currently in development. Clinical trial information: NCT03307044.
Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis
Ebadi, Maryam , Bhanji, Rahima A. , Lytvyak, Ellina , Mason, Andrew L. , Czaja, Albert J. , Montaño‐Loza, Aldo J. , Mason, Andrew , Czaja, A J , Montano-Loza, Aldo J , Mazurak, Vera Christine , Lytvyak, Ellina

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 28, 2018 | Volume: 49 | Issue: 2 | Pages: 173-182

10.1111/apt.15029 | PMID 30484857 Get It

SummaryBackgroundVitamin D deficiency has been implicated in the outcome of chronic liver disease.AimTo determine the frequency of severe vitamin D deficiency in autoimmune hepatitis (AIH), assess its association with treatment non‐response, and evaluate the relationship between vitamin D status and liver‐related mortality and need for transplantation.MethodsTwo hundred and nine patients were evaluated by liver tissue examination at presentation. Serum vitamin D levels were determined, and serum levels <25 nmol/L (10 ng/mL) were considered severely deficient. Treatment non‐response was defined as non‐normalised aspartate aminotransferase/alanine aminotransferase and immunoglobulin G levels during conventional immunosuppressive therapy. Univariate and multivariate analyses were performed using binary logistic regression and Cox proportional hazards model.ResultsThe mean vitamin D level was 60 ± 38 nmol/L (range, 3‐263 nmol/L), and 42 patients (20%) had severe vitamin D deficiency. Treatment non‐response was more common in patients with severe vitamin D deficiency than in patients without (59% vs 41%, P = 0.04). Severe vitamin D deficiency was also independently associated with a higher risk of developing cirrhosis (HR 3.40; 95% CI 1.30‐8.87, P = 0.01) and liver‐related mortality or requirement for liver transplantation (LT; HR 5.26, 95% CI, 1.54‐18.0, P = 0.008). Patients with persistent severe deficiency following vitamin D supplementation continued to have poor outcomes.ConclusionsSevere vitamin D deficiency is associated with treatment non‐response, progression to cirrhosis, and liver‐related death or need for LT. Severe vitamin D deficiency is a prognostic biomarker in AIH.
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts
Link, Brian K. , Ghesquières, Hervé , Nicolas, Émmanuelle , Thompson, Carrie A. , Traverse‐Glehen, Alexandra , Allmer, Cristine, Ansell, Stephen M. , Salles, Gilles , Link, Brian K , Salles, Gilles A , Sarkozy, Clémentine , Maurer, Matthew J. , Nicolas, Emmanuelle, Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Bachy, Emmanuel , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | November 27, 2018 | Volume: 37 | Issue: 2 | Pages: 144-152

10.1200/jco.18.00400 | PMID 30481079 Get It

Purpose Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. Patients and Methods We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 and 2012 in the University of Iowa and Mayo Clinic Specialized Program of Research Excellence (SPORE; N = 920; median follow-up 84 months). COD was classified as being a result of lymphoma, other malignancy, treatment related, or all other causes. Results Ten-year overall survival was comparable in the French (80%) and US (77%) cohorts. We were able to classify COD in 248 (88%) of 283 decedents. In the overall cohort, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by treatment-related mortality (3.0%), other malignancy (2.9%), other causes (2.2%), and unknown (3.0%). The 10-year cumulative incidence of death as a result of lymphoma or treatment was higher than death as a result of all other causes for each age group (including patients ≥ 70 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score 0 to 1 (4.0% v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.1% v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7% v 5.7%); and for patients with a history of transformed FL (45.9% v 4.7%), but not among patients without (8.1% v 6.2%). Overall, 77 of 140 deaths as a result of lymphoma occurred in patients whose FL transformed after diagnosis. Conclusion Despite the improvement in overall survival in patients with FL in the rituximab era, their leading COD remains lymphoma, especially after disease transformation. Treatment-related mortality also represents a concern, which supports the need for less-toxic therapies.
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
Théry, Clotilde , Witwer, Kenneth W. , Aïkawa, Elena , Alcaraz, María José , Anderson, Johnathon D. , Andriantsitohaina, Ramaroson , Antoniou, Anna , Arab, Tanina , Archer, Fabienne , Atkin‐Smith, Georgia K. , Ayre, D. Craig , Bach, Jean‐Marie , Bachurski, Daniel , Baharvand, Hossein , Balaj, Leonora , Baldacchino, Shawn , Bauer, Natalie , Baxter, Amy A. , Bebawy, Mary , Beckham, Carla, Zavec, Apolonija Bedina, Benmoussa, Abderrahim , Berardi, Anna C. , Bergese, Paolo , Bielska, Ewa , Blenkiron, Cherie , Bobis‐Wozowicz, Sylwia , Boilard, Éric , Boireau, Wilfrid , Bongiovanni, Antonella , Borràs, Francesc E. , Bösch, Steffi , Boulanger, Chantal M. , Breakefield, Xandra O. , Breglio, Andrew , Brennan, Meadhbh Á. , Brigstock, David R. , Brisson, Alain , Broekman, Marike L. D. , Bromberg, Jacqueline , Bryl‐Górecka, Paulina , Burger, Dylan , Busatto, Sara , Buschmann, Dominik , Buzás, Edit I. , Byrd, James Brian , Carter, David R. F. , Caruso, Sarah , Chamley, Lawrence W. , Cheng, Lesley , Chin, Andrew R., Clayton, Aled , Clerici, Stefano Piatto , Cocks, Alex, Cocucci, Emanuele , Coffey, Robert J., Cordeiro‐da‐Silva, Anabela , Couch, Yvonne , Coumans, Frank A. W., Coyle, Beth , Crescitelli, Rossella , Criado, Miriã Ferreira, D’Souza‐Schorey, Crislyn , Chaudhuri, Amrita Datta , Candia, Paola de , Santana, Eliezer F De , Wever, Olivier De , Portillo, Hernando A. del , Demaret, Tanguy , Deville, Sarah , Devitt, Andrew , Dhondt, Bert , Vizio, Dolores Di , Rubio, Ana Paula Domínguez , Dourado, Maurício Rocha , Driedonks, Tom A. P. , Duarte, Filipe V. , Duncan, Heather M. , Eichenberger, Ramon M. , Ekström, Karin M. , Andaloussi, Samir EL , Élie-Caille, Céline , Erdbrügger, Uta , Fatima, Farah , Fish, Jason E. , Flores‐Bellver, Miguel , Försönits, András, Frelet‐Barrand, Annie , Fricke, Fabia , Fuhrmann, Gregor , Gámez‐Valero, Ana , Gardiner, Chris , Gärtner, Kathrin , Gaudin, Raphaël , Gho, Yong Song , Giebel, Bernd , Gilbert, Caroline , Gimona, Mario , Giusti, Ilaria , Goberdhan, Deborah C. I. , Görgens, André , Gorski, Sharon M. , Greening, David W. , Gross, Julia Christina , Gualerzi, Alice , Gupta, Gopal N. , Gustafson, Dakota , Handberg, Aase , Haraszti, Reka A. , Harrison, Paul , Hegyesi, Hargita , Hendrix, An , Hill, Andrew F. , Hochberg, Fred H. , Hoffmann, Karl F. , Holder, Beth , Holthöfer, Harry , Hosseinkhani, Baharak , Hu, Guoku , Huang, Yiyao , Huber, Veronica , Hunt, Stuart , Ibrahim, Ahmed , Ikezu, Tsuneya , Inal, Jameel M. , Işın, Mustafa , Ivanova, Alena , Jackson, Hannah K. , Jacobsen, Søren , Jay, Steven M. , Jayachandran, Muthuvel , Jenster, Guido , Jiang, Lanzhou , Johnson, Suzanne M. , Jones, Jennifer , Jong, Ambrose, Jovanović‐Talisman, Tijana , Jung, Stephanie , Kalluri, Raghu , Kano, Shin‐ichi , Kaur, Sukhbir , Kawamura, Yumi , Keller, Evan T. , Khamari, Delaram , Khomyakova, Elena , Kierulf, Peter, Kim, Kwang Pyo , Kislinger, Thomas , Klingeborn, Mikael , Klinke, David J. , Kornek, Miroslaw , Kosanović, Maja , Kovács, Árpád Ferenc , Krämer‐Albers, Eva‐Maria , Krause, Mirja, Kurochkin, Igor V. , Kuypers, Sören , Laitinen, Saara , Langevin, Scott M. , Languino, Lucia R. , Lässer, Cecilia , Laurent, Louise C. , Lázaro‐Ibáñez, Elisa , Lay, Soazig Le , Lee, Myung‐Shin , Lee, Yi , Lemos, Débora S., Lenassi, Metka , Leszczynska, Aleksandra , Li, Isaac T. S. , Liao, Ke , Libregts, Sten F.W.M. , Ligeti, Erzsébet , Lim, Rebecca , Lim, Sai Kiang , Linē, Aija , Linnemannstöns, Karen, Llorente, Alicia , Lorenowicz, Magdalena J. , Lőrincz, Ákos M. , Lovett, Jason , Lowry, Michelle C., Loyer, Xavier , Lu, Quan , Łukomska, Barbara , Lunavat, Taral R. , Marcilla, Antonio , Mariani, Jacopo , Mariscal, Javier , Martens‐Uzunova, Elena S. , Martín‐Jaular, Lorena , Martínez, Maria Carmen , Martins, Vilma R. , Mathieu, Mathilde , Mathivanan, Suresh , Maugeri, Marco , McGinnis, Lynda K. , McVey, Mark J. , Meckes, David G. , Meehan, Katie , Jørgensen, Maléne Møller , Morhayim, Jess , Muraca, Maurizio , Musante, Luca , Mussack, Veronika , Muth, Dillon C. , Myburgh, Kathryn H. , Najrana, Tanbir , Nawaz, Muhammad , Nazarenko, Irina , Nejsum, Peter , Néri, Christian , Nolan, John P. , Hoen, Esther Nm Nolte-'t, Hooten, Nicole Noren , O’Grady, Tina , Ochiya, Takahiro , Olivier, Martin , Ortíz, Alberto , Ortiz, Luis A. , Osteikoetxea, Xabier , Østergaard, Ole , Ostrowski, Matías , Pegtel, D. Michiel , Peinado, Héctor , Perut, Francesca , Pfaffl, Michael W. , Phinney, Donald G. , Pieters, Bartijn C. H. , Pink, Ryan , Pisetsky, David S. , Strandmann, Elke Pogge von , Polakovičová, Iva , Poon, Ivan K. H. , Powell, Bonita H. , Prada, Ilaria , Pulliam, Lynn , Quesenberry, Peter J. , Radeghieri, Annalisa , Raffaı̈, Robert L. , Rak, Janusz , Ramirez, Marcel I. , Raposo, Graça , Rayyan, Morsi , Ricklefs, Franz , Roberts, David D. , Rodrigues, Sílvia C. , Rohde, Eva , Rome, Sophie , Rouschop, Kasper M.A. , Rughetti, Aurelia , Russell, Ashley E. , Sahoo, Susmita , Salas‐Huenuleo, Edison , Sánchez, Catherine , Saugstad, Julie A. , Saul, Meike J. , Schneider, Raphaël , Schøyen, Tine Hiorth , Scott, Aaron , Shahaj, Eriomina , Sharma, Shivani , Shatnyeva, Olga , Shekari, Faezeh , Shelke, Ganesh Vilas , Shiba, Kiyotaka , Siljander, Pia , Silva, Andreia , Skowronek, Agata, Snyder, Orman L., Sódar, Barbara W., Soekmadji, Carolina , Stahl, Philip D., Stoorvogel, Willem , Stott, Shannon L. , Strasser, Erwin , Tahara, Hidetoshi , Tewari, Muneesh , Timms, Kate , Tiwari, Swasti , Tixeira, Rochelle , Toh, Wei Seong , Tomasini, Richard , Tosar, Juan Pablo , Toxavidis, Vasilis, Urbanelli, Lorena , Vader, Pieter , Balkom, Bas WM van, Grein, Susanne G van der, Deun, Jan Van , Herwijnen, Martijn J. C. van , Keuren‐Jensen, Kendall Van , Niel, Guillaume van , Royen, Martin E. van , Wijnen, André J. van , Vasconcelos, M. Helena , Vechetti, Ivan J. , Vella, Laura J. , Velot, Émilie , Verweij, Frederik J. , Vestad, Beate , Viñas, Jose L. , Visnovitz, Tamás , Vukman, Krisztina V , Wahlgren, Jessica, Watson, Dionysios C. , Wauben, Marca H. M. , Weaver, Alissa M. , Webber, Jason , Weber, Viktoria , Wehman, Ann M. , Welsh, Joshua A , Wheelock, Åsa M. , Wiener, Zoltán , Witte, Leonie , Wolfram, Joy , Xagorari, Angeliki , Xander, Patrícia , Xu, Jing , Yan, Xiaomei , Yin, Hang , Yuana, Yuana, Zappulli, Valentina , Zárubová, Jana , Žėkas, Vytautas , Zhang, Jianye , Zhao, Zezhou , Zickler, Antje M. , Zimmermann, Pascale , Zivkovic, Angela M. , Zocco, Davide, Zuba‐Surma, Ewa , Malhi, Harmeet , Peinado, Héctor , van Wijnen, Andre J , Bergese, Paolo , Kim, Kwang Pyo , Ikezu, Tsuneya , Wolfram, Joy , Lenassi, Metka , Gualerzi, Alice , Nazarenko, Irina , Pink, Ryan , Siljander, Pia R-M , Welsh, Joshua A , Witwer, Kenneth W , Hill, Andrew F , Coyle, Beth , Saugstad, Julie A , Buch, Shilpa J. , Buck, Amy H. , Bussolati, Benedetta , Camussi, Giovanni , Chang, Yu‐Ting , Chen, Chihchen , Chen, Daiwen , Criado, Miriã Ferreira , Das, Saumya , Dieterich, Lothar C. , Dolo, Vincenza , Dominici, Massimo , Falcón‐Pérez, Juan Manuel , Gabrielsson, Susanne , Khvorova, Anastasia , Krasemann, Susanne , Kusuma, Gina Diamanta , Lannigan, Joanne , Laurent, Louise C , Lavieu, Grégory , Lombard, Catherine Anne , Lötvall, Jan , Maas, Sybren L. N. , Mertens, Inge , Minciacchi, Valentina R. , Möller, Andreas , Morales‐Kastresana, Aizea , Mullier, François , Neri, Tommaso , Nieuwland, Rienk , Nimrichter, Leonardo , O’Driscoll, Lorraine , O’Loghlen, Ana , Park, Jaesung , Raimondo, Stefania , Regev‐Rudzki, Neta , Robbins, Paul D. , Saá, Paula , Schiffelers, Raymond Michel , Shetty, Ashok Kumar , Soares, Rodrigo Pedro , Sotillo, Javier , Swift, Simon , Tkach, Mercedes , Torrecilhas, Ana Cláudia , Balkom, Bas W. M. van , Grein, Susanne G. van der, Veit, Tiago Degani , Weiss, Daniel J. , Wendt, Sebastian, Yáñez‐Mó, María , Zheng, Lei , Zheutlin, Alexander R. , Borràs, Francesc E , Martens-Uzunova, Elena S , Buzas, Edit I , Giebel, Bernd , Jones, Jennifer C , Ortiz, Alberto , Greening, David W

Mayo Clinic

Journal of Extracellular Vesicles | November 24, 2018 | Volume: 7 | Issue: 1 | Pages: No page available

10.1080/20013078.2018.1535750 | PMID 30637094 Get It

ABSTRACT The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell‐released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV‐associated functional activities. Finally, a checklist is provided with summaries of key points.
Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma
Kumar, Shaji , Grząśko, Norbert , Wiktor-Jędrzejczak, W , Grosicki, Sebastian , Kyrtsonis, Marie‐Christine , Spencer, Andrew , Gupta, Neeraj , Teng, Zhaoyang , Byrne, Catriona , Labotka, Richard, Kumar, Shaji K , Gupta, Neeraj , Dimopoulos, Meletios A , Delimpasi, Sosana , Dimopoulos, Meletios Α.

Mayo Clinic

British Journal of Haematology | November 21, 2018 | Volume: 184 | Issue: 4 | Pages: 536-546

10.1111/bjh.15679 | PMID 30460684 Get It

SummaryThere is a need for efficacious, convenient treatments with long‐term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all‐oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m2 on days 1, 8 and 15, and dexamethasone 40 mg on days 1, 8, 15 and 22 in 28‐day cycles. The primary endpoint was overall response rate (ORR). Seventy‐eight patients were enrolled (median age 63·5 years). At data cut‐off, patients had received a median of 12 treatment cycles; 31% remained on treatment. ORR was 48% [16% very good partial response or better (≥VGPR)]. ORR was 64% and 32% in patients aged ≥65 and <65 years (25% and 16% ≥VGPR), respectively. At a median follow‐up of 15·2 months, median progression‐free survival (PFS) was 14·2 months, with a trend towards better PFS in patients aged ≥65 years vs. <65 years (median 18·7 months vs. 12·0 months; hazard ratio 0·62, P = 0·14). ICd was well tolerated. The most common treatment‐emergent adverse events were diarrhoea (33%), nausea (24%), upper respiratory tract infection (24%), and thrombocytopenia (22%); 10 patients (13%) had peripheral neuropathy (one grade 3). This study is registered at ClinicalTrials.gov (NCT02046070).
Use of Ivermectin in Neurocysticercosis: A Case Report
Samannodi, Mohammed , Zhao, Andrew , Hasbun, Rodrigo

Mayo Clinic

American Journal of Case Reports | November 20, 2018 | Volume: 19 | Issue: No issue available | Pages: 1378-1381

10.12659/ajcr.911269 | PMID 30455413 Get It

Reply: Risk of fall injury in patients taking proton pump inhibitors—a meta-analysis
Lapumnuaypol, Kamolyut , Thongprayoon, Charat , Wijarnpreecha, Karn , Tiu, Andrew , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Thongprayoon, Charat , Wijarnpreecha, Karn

Mayo Clinic

QJM: An International Journal of Medicine | November 19, 2018 | Volume: 112 | Issue: 4 | Pages: 319-319

10.1093/qjmed/hcy274 | PMID 30476239 Get It